A phase I clinical trial has found that a new tablet vaccine may be a safe and effective method for protecting against H1N1 seasonal influenza. The tablet vaccine was developed by Vaxart, a private company established in 2004 that develops oral vaccines. This new vaccine has the potential to change the flu vaccine industry since it features a painless delivery and 6 month room temperature shelf life. The next step for the tablet will be a phase Ib follow-up trial. “These studies show that we are closing in on an effective influenza vaccine that is administered using a simple, user-friendly tablet,” said Vaxart CEO Wouter Latour, MD. “We are eager to make these public health benefits a reality.”
Read more here
